Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients
Vergara-Rodriguez P, Tozzi MJ, Botsko M, Nandi V, Altice F, Egan JE, O'Connor PG, Sullivan LE, Fiellin DA. Hepatic Safety and Lack of Antiretroviral Interactions With Buprenorphine/Naloxone in HIV-Infected Opioid-Dependent Patients. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s62-s67. PMID: 21317596, DOI: 10.1097/qai.0b013e31820a820f.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid-dependent patientsMedian aspartate aminotransferasePharmacodynamic interactionsAspartate aminotransferaseBup/ALT valuesAlanine aminotransferaseBUP/NXOpioid-dependent HIVProspective cohort studyHepatic safetyHepatitis CCohort studyHepatic toxicityHIVPatientsAtazanavirNaloxonePrior reportsExposure measuresSignificant decreaseAminotransferaseSignificant changesTreatmentImproved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics
Korthuis PT, Tozzi MJ, Nandi V, Fiellin DA, Weiss L, Egan JE, Botsko M, Acosta A, Gourevitch MN, Hersh D, Hsu J, Boverman J, Altice FL. Improved Quality of Life for Opioid-Dependent Patients Receiving Buprenorphine Treatment in HIV Clinics. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s39-s45. PMID: 21317593, PMCID: PMC3073082, DOI: 10.1097/qai.0b013e318209754c.Peer-Reviewed Original ResearchConceptsSF-12 scoresGeneral US populationOpioid dependenceUS populationPoor health-related qualityShort Form Health SurveyBUP/NXBuprenorphine/naloxoneHIV care settingsOpioid-dependent patientsOpioid-dependent personsForm Health SurveyHealth-related qualityQuality of lifeBup/Mean HRQoLHIV clinicMaintenance therapyBuprenorphine treatmentHIV infectionPhysical HRQoLMental HRQOLHRQoL domainsMixed effects regressionHealth SurveyIntegration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative
Weiss L, Netherland J, Egan JE, Flanigan TP, Fiellin DA, Finkelstein R, Altice FL. Integration of Buprenorphine/Naloxone Treatment into HIV Clinical Care: Lessons From the BHIVES Collaborative. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2011, 56: s68-s75. PMID: 21317597, DOI: 10.1097/qai.0b013e31820a8226.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAnti-HIV AgentsBuprenorphineBuprenorphine, Naloxone Drug CombinationDelivery of Health Care, IntegratedHealth ResourcesHealth Services Needs and DemandHIV InfectionsHumansNaloxoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPrimary Health CareSubstance Abuse Treatment CentersUnited StatesConceptsBUP/NXHIV clinical careBup/HIV evaluationClinical careBuprenorphine/naloxone treatmentGeneral internal medicine physiciansHospital-based clinicsInternal medicine physiciansSite principal investigatorsExperiences of physiciansMental health issuesPrincipal investigatorHIV providersMultisubstance useNX treatmentHIV careIntegrated HIVNaloxone treatmentUrine toxicologyMultiple prescribersHIV treatmentMedicine physiciansTreatment servicesProvider experience